A small-molecule inhibitor of integrin α2β1 introduces a new strategy for antithrombotic therapy

Summary

Interaction of blood platelets with vascular collagen is an initiating event in haemostasis and thrombus formation. Based on molecular modelling of human integrin α2I domain and cell-based screening assays we have developed sulfonamide derivatives, a mechanistically novel class of molecules. These molecules show antiplatelet efficacy by selectively inhibiting α2β1 integrin-mediated collagen binding. One sulfonamide derivative, named BTT-3016, showed inhibitory capacity in several assessments of human platelet interaction with collagen. It inhibited about 90% of the aggregation of gel-filtered magnesium-supplemented platelets and 70% of aggregation in PPACK-anticoagulated platelet-rich plasma when stimulated with collagen but not with ADP. The antiplatelet activity of BTT-3016 was dependent on α2β1 integrin, since in collagen binding test BTT-3016 had no effect on the platelets derived from α2 integrin null mice. When tested in an in vivo model in mice, BTT-3016 clearly reduced thrombus formation on the vessel wall after vascular injury. Furthermore, BTT-3016 prolonged tail-bleeding time in a manner comparable to aspirin. We show that new α2β1 inhibitors exert collagen-specific antiplatelet activity and regulate thrombus growth in vivo without compromising primary haemostasis more than aspirin. We suggest that the α2β1 inhibiting strategy could be further developed for the prevention and treatment of arterial thrombosis.

Keywords

Integrin - collagen - platelet - antithrombotic therapy

^* These authors contributed equally.

• References

• 1 Holtkotter O, Nieswandt B, Smyth N. et al. Integrin alpha2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J Biol Chem 2002; 277: 10789-10794.
• 2 Chen J, Diacovo TG, Grenache DG. et al. The alpha(2) integrin subunit-deficient mouse: a multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am J Pathol 2002; 161: 337-344.
• 3 Sarratt KL, Chen H, Zutter MM. et al. GPVI and α2β1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow. Blood 2005; 106: 1268-1277.
• 4 He L, Pappan LK, Grenache DG. et al. The contributions of the α2β1 integrin to vascular thrombosis in vivo . Blood 2003; 102: 3652-3657.
• 5 Kuijpers MJE, Pozgajova M, Cosemans JMEM. et al. Role of murine integrin α2β1 in thrombus stabilization and embolization: Contribution of thromboxane A2. Thromb Haemost 2007; 98: 1072-1080.
• 6 Nieuwenhuis HK, Akkerman JW, Houdijk WP. et al. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985; 318: 470-472.
• 7 Nieuwenhuis HK, Sakariassen KS, Houdijk WP. et al. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood 1986; 68: 692-695.
• 8 Nieswandt B, Brakebusch C, Bergmeier W. et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. Embo J 2001; 20: 2120-2130.
• 9 Gruner S, Prostredna M, Koch M. et al. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood 2005; 105: 1492-1499.
• 10 Ni H, Yuen PS, Papalia JM. et al. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci USA 2003; 100: 2415-2419.
• 11 Kunicki TJ, Ruggeri ZM. Platelet collagen receptors and risk prediction in stroke and coronary artery disease. Circulation 2001; 104: 1451-1453.
• 12 Santoso S, Kunicki TJ, Kroll H. et al. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999; 93: 2449-2453.
• 13 Moshfegh K, Wuillamin WA, Redondo M. et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999; 353: 351-354.
• 14 Carlsson LE, Santoso S, Spitzer C. et al. The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999; 93: 3583-3586.
• 15 Matsubara Y, Murata M, Maruyama T. et al. Association between diabetic retinopathy and genetic variations in alpha2beta1 integrin, a platelet receptor for collagen. Blood 2000; 95: 1560-1564.
• 16 Dodson PM, Haynes J, Starczynski J. et al. The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion. Eye 2003; 17: 772-777.
• 17 Croft SA, Hampton KK, Sorrell JA. et al. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol 1999; 106: 771-776.
• 18 Nikolopoulos GK, Tsantes AE, Bagos PG. et al. Integrin, alpha2 gene C807T polymorphism and risk of ischemic stroke: A meta-analysis. Thromb Res 2007; 119: 501-510.
• 19 Coller BS, Beer JH, Scudder LE. et al. Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. Blood 1989; 74: 182-192.
• 20 Yin H, Gerlach LO, Miller MW. et al. Arylamide derivatives as allosteric inhibitors of the integrin alpha2beta1/type I collagen interaction. Bioorg Med Chem Lett 2006; 16: 3380-3382.
• 21 Käpylä J, Pentikäinen O, Nyrönen T. et al. A small molecule designed to target metal binding site in alpha2I domain inhibits integrin function. J Med Chem 2007; 50: 2742-2746.
• 22 Choi S, Vilaire G, Marcinkiewicz C. et al. Small molecule inhibitors of alpha2beta1. J Med Chem 2007; 50: 5457-5462.
• 23 Emsley J, King SL, Bergelson JM. et al. Crystal structure of the I domain from integrin alpha2beta1. J Biol Chem 1997; 272: 28512-28517.
• 24 Berman HM, Westbrook J, Feng Z. et al. The Protein Data Bank. Nucleic Acids Res 2000; 28: 235-242.
• 25 Lehtonen JV, Still DJ, Rantanen VV. et al. BODIL: a molecular modeling environment for structure-function analysis and drug design. J Comput Aided Mol Des 2004; 18: 401-419.
• 26 Käpylä J, Ivaska J, Riikonen R. et al. Integrin alpha(2)I domain recognizes type I and type IV collagens by different mechanisms. J Biol Chem 2000; 275: 3348-3354.
• 27 Ivaska J, Reunanen H, Westermarck J. et al. Integrin alpha2beta1 mediates iso-form-specific activation of p38 and upregulation of collagen gene transcription by a mechanism involving the alpha2 cytoplasmic tail. J Cell Biol 1999; 147: 401-416.
• 28 Nykvist P, Tu H, Ivaska J. et al. Distinct recognition of collagen subtypes by alpha(1)beta(1) and alpha(2)beta(1) integrins. Alpha(1)beta(1) mediates cell adhesion to type XIII collagen. J Biol Chem 2000; 275: 8255-8261.
• 29 Koistinen P, Heino J. The selective regulation of αVβ1 integrin expression is based on the hierarchical formation of αV-containing heterodimers. J Biol Chem 2002; 277: 24835-24841.
• 30 Tulla M, Pentikainen OT, Viitasalo T. et al. Selective binding of collagen subtypes by integrin alpha1I, alpha2I, and alpha10I domains. J Biol Chem 2001; 276: 48206-48212.
• 31 Ilveskero S, Siljander P, Lassila R. Procoagulant activity on platelets adhered to collagen or plasma clot. Arterioscler Thromb Vasc Biol 2001; 21: 628-635.
• 32 Mustonen P, Lassila R. Epinephrine augments platelet recruitment to immobilized collagen in flowing blood-evidence for a von Willebrand factor-mediated mechanism. Thromb Haemost 1996; 75: 175-181.
• 33 Timmons S, Hawiger J. Isolation of human platelets by albumin and gel filtration. Methods Entymol 1989; 169: 11-21.
• 34 Hall CL, Taubman MB, Nemerson Y. et al. Factor Xa generation at the surface of cultured rat vascular smooth muscle cells in an in vitro flow system. J Biomech Eng 1998; 120: 484-490.
• 35 Born GRV. Quantitative investigation into the aggregation of blood platelets. J Physiol 1962; 162: 67-68.
• 36 Siljander P, Lassila R. Studies of adhesion-dependent platelet activation: distinct roles for different participating receptors can be dissociated by proteolysis of collagen. Arterioscler Thromb Vasc Biol 1999; 19: 3033-3043.
• 37 Ilveskero S, Lassila R. Abciximab inhibits procoagulant activity but not the release reaction upon collagen- or clot-adherent platelets. J Thromb Haemost 2003; 1: 805-813.
• 38 Emsley J, Knight CG, Farndale RW. et al. Structural basis of collagen recognition by integrin α2β1. Cell 2000; 335: 1019-1028.
• 39 Mirtti T, Nylund C, Lehtonen J. et al. Regulation of prostate cell collagen receptors by malignant transformation. Int J Cancer 2006; 118: 889-898.
• 40 Kamata T, Puzon W, Takada Y. Identification of putative ligand binding sites within I domain of integrin α2β1 (VLA-2, CD49b/CD29). J Biol Chem 1994; 269: 9659-9663.
• 41 Sato S, Futaki F, Fukuchi N. et al. A new nucleoside derivative, AJP117510, as an inhibitor of integrin alpha2beta1 collagen binding. J Antibiot 2006; 59: 251-253.
• 42 Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003; 2: 703-716.
• 43 Miller MW, Basra S, Kulp DW. et al. Small-molecule inhibitors of integrin α2β1 that prevent pathological thrombus formation via an allosteric mechanism. PNAS 2009; 106: 719-724.